At the recent AACC annual scientific meeting, Melissa Snyder, Ph.D., Consultant in the Division of Clinical Biochemistry and Immunology at Mayo Clinic in Rochester, Minnesota, presented the short course, “Clinical and Laboratory Aspects of...
Leslie Donato, Ph.D., DABCC, Co-Director of the Cardiovascular Laboratory Medicine and Co-Director of the Hospital Clinical Laboratory and Point-of-Care Testing at Mayo Clinic in Rochester, recently authored an article in Clinical...
Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic in Rochester, recently authored an article in Clinical Laboratory News that discusses patient fasting in lipid testing. While...
Sleep Disorder Testing - Mayo Clinic Laboratories
Determining orexin-A/ hypocretin-1 levels through CSF testing provides a sensitive and specific result to guide appropriate treatment for patients.
Enhancing Personalized Medicine with Cardiovascular Genomics - Insights
PACE / State of FLIn this month’s “Virtual Lecture” Linnea Baudhuin, Ph.D., professor of laboratory medicine and pathology in the division of laboratory genetics and genomics, discusses inherited cardiovascular conditions and identifies...
IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL) - Insights
In this month’s “Hot Topic,” Curtis Hanson, M.D., will discuss the use of laboratory-based prognostic markers in patients with chronic lymphocytic leukemia (CLL). He will also highlight the importance of molecular analyses for IGHV and TP53...
Patient-focused pragmatism: The Mayo Clinic innovation model - Insights
In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides...
Improving diagnosis of rare congenital disorders - Insights
Experts at Mayo Clinic have developed a unique method of testing that combines new technology with novel bioinformatics to promptly detect a group of uncommon genetic conditions that are often difficult to identify.
Testing for a surprising antigen enables insight into a chronic kidney illness - Insights
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about...
IgA-mediated autoimmune bullous dermatoses - Insights
In this month’s “Hot Topic,” Julia Lehman, M.D., will discuss autoimmune bullous dermatoses, the rare category of blistering skin diseases that are caused by the development of autoantibodies against various constitutive parts of the...